Literature DB >> 17406620

Data analysis of assorted serum peptidome profiles.

Josep Villanueva1, John Philip, Lin DeNoyer, Paul Tempst.   

Abstract

Discovery of biomarker patterns using proteomic techniques requires examination of large numbers of patient and control samples, followed by data mining of the molecular read-outs (e.g., mass spectra). Adequate signal processing and statistical analysis are critical for successful extraction of markers from these data sets. The protocol, specifically designed for use in conjunction with MALDI-TOF-MS-based serum peptide profiling, is a data analysis pipeline, starting with transfer of raw spectra that are interpreted using signal processing algorithms to define suitable features (i.e., peptides). We describe an algorithm for minimal entropy-based peak alignment across samples. Peak lists obtained in this way, and containing all samples, all peptide features and their normalized MS-ion intensities, can be evaluated, and results validated, using common statistical methods. We recommend visual inspection of the spectra to confirm all results, and have written freely available software for viewing and color-coding of spectral overlays.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406620     DOI: 10.1038/nprot.2007.57

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  8 in total

1.  Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment.

Authors:  Maureen B Tracy; Haijian Chen; Dennis M Weaver; Dariya I Malyarenko; Maciek Sasinowski; Lisa H Cazares; Richard R Drake; O John Semmes; Eugene R Tracy; William E Cooke
Journal:  Proteomics       Date:  2008-04       Impact factor: 3.984

2.  Strategy for degradomic-peptidomic analysis of human blood plasma.

Authors:  Yufeng Shen; Tao Liu; Nikola Tolić; Brianne O Petritis; Rui Zhao; Ronald J Moore; Samuel O Purvine; David G Camp; Richard D Smith
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

3.  Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.

Authors:  P Kelly; V Appleyard; K Murray; F Paulin; D Lamont; L Baker; S Suttie; D Exon; A Thompson
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

4.  Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry.

Authors:  Josep Villanueva; Arpi Nazarian; Kevin Lawlor; Paul Tempst
Journal:  Nat Protoc       Date:  2009-07-23       Impact factor: 13.491

5.  Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Authors:  Arpi Nazarian; Kevin Lawlor; San San Yi; John Philip; Mousumi Ghosh; Mariana Yaneva; Josep Villanueva; Alan Saghatelian; Melissa Assel; Andrew J Vickers; James A Eastham; Howard I Scher; Brett S Carver; Hans Lilja; Paul Tempst
Journal:  Mol Cell Proteomics       Date:  2014-07-23       Impact factor: 5.911

6.  Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays.

Authors:  Meital Cohen; Rami Yossef; Tamir Erez; Aleksandra Kugel; Michael Welt; Mark M Karpasas; Jonathan Bones; Pauline M Rudd; Julien Taieb; Herve Boissin; Dror Harats; Karin Noy; Yoram Tekoah; Rachel G Lichtenstein; Eitan Rubin; Angel Porgador
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

7.  Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass spectrometry.

Authors:  Nichola C Garbett; Michael L Merchant; C William Helm; Alfred B Jenson; Jon B Klein; Jonathan B Chaires
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.

Authors:  Johannes Voortman; Thang V Pham; Jaco C Knol; Giuseppe Giaccone; Connie R Jimenez
Journal:  Proteome Sci       Date:  2009-09-03       Impact factor: 2.480

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.